GTC
AERI

Ghost Tree Capital’s Aerie Pharmaceuticals AERI Stock Holding History

Ghost Tree Capital’s Portfolio AERI Stock Details AERI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-220,000
Closed -$9.98M – 82
2017
Q1 		$9.98M Buy
+220,000
New +$9.81M 1.86% 16
2016
Q4 		– Sell
-300,000
Closed -$11.3M – 100
2016
Q3 		$11.3M Buy
+300,000
New +$6.62M 1.84% 13

Other funds holding AERI

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.32B AUM 28.11% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Ghost Tree Capital's AERI Position: Q1 2020 in Review

Ghost Tree Capital sold out of Aerie Pharmaceuticals (AERI) in Q1 2020, closing a stake of 575,000 shares — an estimated $13.9M sold.

Ghost Tree Capital first reported a position in AERI in Q3 2016 and held it in 5 quarters. The position peaked at $13.9M in Q4 2019. 155 funds tracked by Wall St. Rank hold AERI as of Q1 2020.

  • Ghost Tree Capital reported no remaining Aerie Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Ghost Tree Capital sold 575,000 Aerie Pharmaceuticals shares in Q1 2020, an estimated $13.9M.
  • Ghost Tree Capital first reported a position in Aerie Pharmaceuticals in Q3 2016 and held it in 5 quarters.
  • Ghost Tree Capital's Aerie Pharmaceuticals position peaked at $13.9M in Q4 2019.
  • 155 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q1 2020.

Based on Ghost Tree Capital's 13F filing for Q1 2020, filed 15 May 2020.